BCM
AERI

Bienville Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Bienville Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,000
Closed -$204K – 95
2014
Q4 		$204K Buy
+7,000
New +$178K 0.17% 87

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Bienville Capital Management's AERI Position: Q1 2015 in Review

Bienville Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2015, closing a stake of 7,000 shares — an estimated $204K sold.

Bienville Capital Management first reported a position in AERI in Q4 2014 and held it in 1 quarter. The position peaked at $204K in Q4 2014. 123 funds tracked by Wall St. Rank hold AERI as of Q1 2015.

  • Bienville Capital Management reported no remaining Aerie Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 7,000 Aerie Pharmaceuticals shares in Q1 2015, an estimated $204K.
  • Bienville Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's Aerie Pharmaceuticals position peaked at $204K in Q4 2014.
  • 123 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.